On the strength of successful strategic choices, Exosens is accelerating its growth

The excellent 2024 results (+35% sales, +37.8% EBITDA, +66.7% net profit) illustrate the relevance of the strategic choices made by Exosens with the support of HLD and point to dynamic and sustainable growth for the Group. After a successful IPO and bolt-on acquisitions, Exosens is to invest €20m in a new plant in the United States to increase its production capacity and meet demand from the defence market, while benefiting from additional market opportunities. Congratulations to Jérôme Cerisier and all his teams around the world for this remarkable growth dynamic.